CORZ
Core Scientific, Inc.
Stock
$16.45+0.10 (+0.61%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $440M | $319M | $511M | $502M | $640M | $544M | $60M |
| Cost of revenue | $316M | $281M | $390M | $379M | $632M | $306M | $51M |
| Gross profit | $125M | $38M | $121M | $123M | $8.4M | $239M | $9.4M |
| R&D | — | — | $12M | $7.2M | $27M | $7.7M | $5.3M |
| SG&A | — | $159M | $114M | $108M | $226M | $65M | $16M |
| Other operating expenses | — | $124M | $138M | — | $1.9B | $35M | — |
| Operating income | −$561M | −$246M | −$142M | $9.0M | −$2.1B | $131M | −$6.3M |
| Non-operating income | −$867M | −$42M | −$1.3B | −$255M | −$54M | −$68M | −$5.9M |
| Pretax income | −$1.4B | −$288M | −$1.4B | −$246M | −$2.2B | $63M | −$12M |
| Taxes | $2.7M | $583K | $859K | $683K | −$17M | $16M | $0 |
| Net income | −$1.4B | −$289M | −$1.4B | −$246M | −$2.1B | $47M | −$12M |
| Diluted EPS | −$4.13 | −$0.88 | −$4.87 | −$0.65 | −$6.30 | $0.20 | −$0.14 |
| Diluted shares | — | 318.1M | 255.8M | 379.9M | 340.6M | 233.3M | 157.6M |
| Revenue growth | — | −37.5% | +1.6% | −21.5% | +17.6% | +802.7% | — |
| Gross margin | 28.3% | 11.9% | 23.7% | 24.6% | 1.3% | 43.9% | 15.6% |
| Operating margin | −127.4% | −77.0% | −27.8% | 1.8% | −329.5% | 24.2% | −10.5% |
| Net margin | −324.9% | −90.5% | −281.6% | −49.1% | −335.2% | 8.7% | −20.2% |